Long-Acting Amylin Analogue

Cagrilintide

Once-Weekly Amylin Receptor Agonist • Investigational Weight-Management Peptide

Cagrilintide is a long-acting amylin analogue studied as a once-weekly treatment for obesity, both alone and with semaglutide as CagriSema. It engages amylin and calcitonin receptors rather than GLP-1, GIP, or glucagon receptors, adding a separate satiety pathway.

Satiety Support Once Weekly Amylin Pathway Phase 3 Evidence

Protocol Snapshot

Cagrilintide Quick Reference

Verified Vendors

Cagrilintide

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Starting Dose

0.25mg

Once weekly for the first four weeks in the phase 3 titration framework.

Target Dose

2.4mg

Once weekly after gradual four-week escalation steps.

Route

SubQ

Long-acting formulation studied as a weekly injection.

Evidence

Phase 3

Strongest evidence is for CagriSema, not untested peptide combinations.

Peptide Grade

GradeB

Weekly amylin agonism has substantial clinical weight-loss support, especially in combination research, but gastrointestinal tolerability and investigational single-agent use keep cagrilintide below the top tier.

Research Community Safety

Substantial clinical evidence for cagrilintide and CagriSema, balanced against investigational status and meaningful gastrointestinal tolerability concerns.

Foundation

Research context, mechanisms, and practical use cases

What Is Cagrilintide?

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone released alongside insulin after meals. Amylin contributes to satiety, slows gastric emptying, and helps regulate post-meal glucose.

Natural amylin is short-lived. Cagrilintide was engineered for prolonged activity that supports once-weekly administration. Its receptor pathway is distinct from GLP-1, GIP, and glucagon agonism.

Separate Satiety Pathway

Cagrilintide adds amylin-pathway signaling rather than another GLP-1 signal. This provides the mechanistic rationale for combining it with semaglutide, although additive gastrointestinal effects remain important.

Clinical Development Context

The strongest evidence comes from CagriSema, the fixed-dose combination of cagrilintide and semaglutide. In REDEFINE 1, CagriSema produced a mean 20.4% weight reduction at 68 weeks using the treatment-policy estimand; 60% of participants lost at least 20%, and approximately 23% lost at least 30%.

Cagrilintide also produced dose-dependent standalone weight loss in phase 2 research. The 4.5mg group lost approximately 10.8% over 26 weeks, compared with approximately 9% with daily liraglutide 3mg.

In 2026, REDEFINE 4 found substantial weight loss with CagriSema but did not demonstrate non-inferiority to tirzepatide. This reinforces that CagriSema is effective, while limiting claims that it is categorically superior to other leading obesity therapies.

Cagrilintide Benefits

The most credible benefits come from randomized trials of cagrilintide alone and CagriSema. Results from semaglutide combinations should not be assumed to apply identically to tirzepatide or retatrutide combinations.

Weight Reduction

Cagrilintide alone and CagriSema have produced clinically meaningful, dose-dependent weight loss in controlled trials.

Distinct Satiety Mechanism

Amylin-receptor activity adds a pathway separate from GLP-1, GIP, and glucagon receptor agonism.

Glycemic Improvement

CagriSema trials in type 2 diabetes reported improvements in HbA1c and body weight.

Once-Weekly Dosing

Its extended activity supports a weekly injection schedule.

Reduced Food Noise

Users and trial participants often describe stronger fullness and reduced persistent hunger.

Standalone Activity

Phase 2 data indicates that cagrilintide has meaningful weight-management activity independent of semaglutide.

Protocol Planning

Dosing, cycling, and preparation

Cagrilintide Dosing Protocol

This schedule mirrors the cagrilintide component used in phase 3 CagriSema development. Research-peptide products are not manufacturer-tested CagriSema formulations, and combinations with tirzepatide or retatrutide have not been validated in controlled trials.

Phase 3 Titration

Weeks 1–4

0.25mg once weekly

Weeks 5–8

0.5mg once weekly

Weeks 9–12

1mg once weekly

Weeks 13–16

1.7mg once weekly

Week 17+

2.4mg once weekly

Titration Notes

Escalation

Advance only when the current dose is tolerated

Strong Effects

Remain at the current step longer rather than rushing escalation

Meals

Smaller meals may reduce nausea and excessive fullness during escalation

Consistency

Use the same administration day each week

Combination Boundary

The controlled phase 3 combination is CagriSema. Cagrilintide plus tirzepatide or retatrutide remains unstudied. Separate mechanisms do not eliminate additive nausea, vomiting, constipation, dehydration, or medication-absorption concerns.

Cagrilintide Reconstitution

The example below uses a 10mg vial with 2mL of bacteriostatic water.

Mixing Details

Vial Size

10mg

BAC Water

2mL

Concentration

5mg/mL

Syringe

U-100 insulin syringe

Reconstitution Calculator

Draw Volumes

0.25mg

5 units

0.5mg

10 units

1mg

20 units

1.7mg

34 units

2.4mg

48 units

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users often describe a distinct physical feeling of fullness rather than only reduced mental cravings.
Some report that large meals or overeating become physically difficult because food feels as though it remains in the stomach longer.
Some users report breaking weight-loss plateaus after adding cagrilintide to an existing protocol.

Negative Reports

Moderate-to-severe fatigue is reported during the first few weeks or after dose increases. Some users say it improves with adaptation, although persistent or severe fatigue warrants medical evaluation.
Nausea, excessive fullness, constipation, and reduced ability to eat enough protein are recurring complaints.
Some users find the physical satiety sensation unpleasant or more difficult to manage than GLP-1-related appetite suppression.

Stacking & Synergy

Potential Cagrilintide pairings and tracking context

The evidence base differs sharply by combination. Mechanistic complementarity is not a substitute for controlled safety data.

Cagrilintide + Semaglutide

CagriSema is the researched combination with phase 3 evidence and a manufacturer-tested fixed-dose formulation.

Cagrilintide + Retatrutide

Amylin signaling may complement retatrutide’s GLP-1/GIP/glucagon activity, but the combination has not been tested in controlled trials.

Cagrilintide + Tirzepatide

This pairing is also unstudied and may intensify gastrointestinal and hydration-related adverse effects.

Outside a manufacturer-tested fixed-dose formulation, use separate injections and separate injection sites. Do not mix cagrilintide with another peptide in the same vial or syringe.

Free with login

Track in Journal

Track Cagrilintide with the appetite, nutrition, and tolerability markers that matter most for this compound.

Weekly dose, injection day, titration step, and combination context.
Hunger, fullness, food noise, meal size, and protein intake.
Nausea, bowel habits, fatigue, hydration, weight trend, and side effects.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

Cagrilintide Side Effects

Gastrointestinal effects are the most common adverse events and may be more pronounced during escalation or when cagrilintide is combined with another appetite-suppressing therapy.

Controlled safety data are strongest for cagrilintide alone and CagriSema. Comparable safety data do not exist for combinations with tirzepatide or retatrutide.

Common Effects

Nausea, sometimes with vomiting.
Constipation or diarrhea.
Abdominal discomfort and excessive fullness.
Marked appetite reduction and fatigue.

Less Common & Urgent Signs

Headache, dizziness, or injection-site reactions.
Hypoglycemia risk is greatest with insulin or sulfonylureas.
Persistent vomiting, severe dehydration, or severe abdominal pain requires medical evaluation.
Rash, swelling, or difficulty breathing requires emergency care.

Cagrilintide Contraindications and Precautions

Use Caution With

History of pancreatitis.
Gallbladder disease.
Gastroparesis or another gastrointestinal motility disorder.
Kidney disease, especially when vomiting or dehydration occurs.
Type 1 diabetes, which has not been established as an appropriate use population.

Drug Interactions

Insulin and sulfonylureas may require clinician-guided adjustment because of hypoglycemia risk.
Delayed gastric emptying may alter the timing of absorption for oral medications, especially drugs requiring rapid or predictable uptake.

Pregnancy and Breastfeeding

Cagrilintide has not been established as safe during pregnancy or breastfeeding. Weight-loss therapy should be avoided during pregnancy.

Regulatory Status

Cagrilintide is not FDA approved as a standalone medication. CagriSema was submitted to the FDA in early 2026 but remains investigational while regulatory review is pending.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We view Cagrilintide as a powerful appetite and metabolic control agent. When paired with Tirzepatide or Retatrutide, it elevates hunger suppression and fat loss results while often smoothing out some of the typical GLP-1 side effects. Community members consistently note more sustainable weight loss and better adherence.

It shines for those who struggle with constant hunger on single agonists. Smart addition to advanced recomp stacks when appetite is the primary barrier.